2-aminoethyl hexadecanoate | 65260-72-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-aminoethyl hexadecanoate
• 英文别名: 2-aminoethyl palmitate；palmitic acid-(2-amino-ethyl ester)；Palmitinsaeure-(2-amino-aethylester)；1-Amino-2-palmitoyloxy-aethan；Palmitoylethanolamid
• CAS: 65260-72-2
• 化学式: C₁₈H₃₇NO₂
• 分子量: 299.497
• InChiKey: KAHYBVSIENJMEL-UHFFFAOYSA-N

物化性质

• 沸点：
  392.7±25.0 °C(Predicted)
• 密度：
  0.899±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  21
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  十六酰胺乙醇 在 四溴化碳 、 三苯基膦 作用下， 以 乙腈 为溶剂， 反应 3.5h， 以65%的产率得到2-aminoethyl hexadecanoate
  参考文献：
  名称：

  Dutta, Pradeep K.; Chaudhuri, Chandana; Mandal, Sukhendu B., Journal of Chemical Research, Miniprint, 1991, # 8, p. 2180 - 2188

  摘要：

  DOI：

文献信息

• Micelle composition of polymer and passenger drug
  申请人：Kwon S. Glen

  公开号：US20060251710A1

  公开（公告）日：2006-11-09

  Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and/or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic drugs for micelle encapsulation may include rapamycin, geldanamycin, and paclitaxel. Administration of these micelle compositions does not require Cremophor EL or Tween 80, avoiding serious side effects associated with these products which would previously accompany such drug administration.

  疏水药物通过封装在胶束组合物中增加溶解度，变得更加实用用于治疗。胶束组合物可能包括辅料生育酚和/或药物的前药配方。胶束延长药物在其中保持的时间，以改善药物循环时间，从而提高药物输送。用于胶束封装的疏水药物可能包括雷帕霉素、格兰达霉素和紫杉醇。这些胶束组合物的给药不需要克雷莫福尔EL或吐温80，避免了与这些产品相关的严重副作用，这些副作用以前会伴随着这种药物的给药。
• Contrast agents
  申请人：——

  公开号：US20040146462A1

  公开（公告）日：2004-07-29

  Ultrasonic visualisation of a subject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration and can therefore act as deposited perfusion tracers. The preparations comprise an injectable aqueous medium comprising dispersed gas and an injectable oil-in-water emulsion in which the oil phase comprises a diffusible component capable of diffusion in vivo into the dispersed gas to promote temporary growth thereof, such that material present at the surfaces of the dispersed gas phase and material present at the surfaces of the dispersed oil phase have affinity for each other, e.g. as a result of having opposite charges. In cardiac perfusion imaging the preparations may advantageously be coadministered with vasodilator drugs such as adenosine in order to enhance the differences between return signal intensity from normal and hypoperfused myocardial tissue respectively.

  使用新型含气对比剂制剂进行超声成像，特别是心肌和其他组织的灌注成像，这些制剂促进体内气相的可控、暂时性生长，因此可以作为沉积的灌注示踪剂。这些制剂包括可注射的水性介质，其中包含分散的气体和可注射的油水乳液，其中油相包含可扩散的成分，能够在体内扩散到分散的气体中促进其暂时性生长，使分散气体相和分散油相表面的物质互相吸引，例如由于具有相反的电荷。在心脏灌注成像中，这些制剂可以优势地与血管扩张药物（如腺苷）同时使用，以增强正常和低灌注心肌组织的回波信号强度差异。
• Acylated insulin
  申请人：NOVO NORDISK A/S

  公开号：EP1132404A2

  公开（公告）日：2001-09-12

  The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ∈-amino group of Lys829; or b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded-for by the genetic code except Lys, Arg and Cys, in any of which cases the ∈-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.

  本发明涉及持久人胰岛素衍生物，其中的 A21 和 B3 氨基酸残基分别是除 Lys、Arg 和 Cys 以外的任何可由遗传密码编码的氨基酸残基；PheB1 可被删除；B30 氨基酸残基是 a) 具有 10 至 24 个碳原子的不可编码的亲脂性氨基酸，在这种情况下，具有最多 5 个碳原子的羧酸酰基与 Lys829 的∈-氨基结合；或 b) B30 氨基酸残基被删除或为除 Lys、Arg 和 Cys 以外的任何可被遗传密码编码的氨基酸残基，在上述任何一种情况下，LysB29 的∈-氨基具有亲脂取代基； 及其任何 Zn2+ 复合物，但条件是当 B30 为 Thr 或 Ala，A21 和 B3 均为 Asn，且存在 PheB1 时，胰岛素衍生物总是作为 Zn2+ 复合物存在。
• NON-FLUORINATED BLOCK COPOLYMER
  申请人：DAIKIN INDUSTRIES, LTD.

  公开号：EP3858881A1

  公开（公告）日：2021-08-04

  Provided is a non-fluorinated block copolymer comprising at least one block segment (A), wherein the block segment (A) comprises a repeating unit formed from one or more types of acrylic monomer having a long-chain hydrocarbon group containing 7-40 carbon atoms, and the block copolymer imparts superior liquid repellency to a base material such as fibers. The non-fluorinated block copolymer preferably contains a segment (B) constituted by at least one of: (B1) a block segment comprising a repeating unit, different from that of segment (A), that is formed from an acrylic monomer having a long-chain hydrocarbon group comprising 7-40 carbon atoms; (B2) a block segment comprising a repeating unit formed from an acrylic monomer not having a long-chain hydrocarbon group; and (B3) a random segment formed from at least two types of acrylic monomers.

  本发明提供了一种无氟嵌段共聚物，该共聚物包含至少一个嵌段（A），其中嵌段（A）包含由一种或多种类型的丙烯酸单体形成的重复单元，该丙烯酸单体具有含有 7-40 个碳原子的长链烃基，并且该嵌段共聚物可为纤维等基材提供优异的憎液性能。无氟嵌段共聚物最好包含由以下至少一种材料构成的嵌段 (B)：(B1) 嵌段，该嵌段包含与嵌段 (A) 不同的重复单元，该重复单元由具有含 7-40 个碳原子的长链烃基的丙烯酸单体形成；(B2) 嵌段，该嵌段包含由不具有长链烃基的丙烯酸单体形成的重复单元；以及 (B3) 由至少两种丙烯酸单体形成的无规嵌段。
• FLUORINE-CONTAINING POLYMER AND SURFACE TREATMENT AGENT
  申请人：DAIKIN INDUSTRIES, LTD.

  公开号：EP3865524A1

  公开（公告）日：2021-08-18

  Provided is a surface treatment agent comprising (A) a fluorine-containing polymer including a repeat unit derived from a fluorine-containing monomer (A1) and a repeat unit derived from a hydrocarbon group-bearing fluorine-free monomer (A2), and (B) a liquid medium. The fluorine-free monomer (A2) is preferably at least one monomer selected from the group consisting of (A2-1) R22-C(=O)-NH-R23-O-R21, (A2-2) CH2=C(-R32)-C(=O)-Y31-Z31(-Y32-R31)n, and (A2-3)X41N(H)r-R41. The surface treatment agent imparts an excellent water/oil repellency to base materials, e.g., fibers.

  本发明提供了一种表面处理剂，该表面处理剂包括 (A) 含氟聚合物，其中包括由含氟单体 (A1) 衍生的重复单元和由含烃基的无氟单体 (A2) 衍生的重复单元；以及 (B) 液体介质。无氟单体（A2）最好是至少一种选自以下组别的单体：(A2-1) R22-C(=O)-NH-R23-O-R21, (A2-2) CH2=C(-R32)-C(=O)-Y31-Z31(-Y32-R31)n, 和 (A2-3)X41N(H)r-R41。表面处理剂可使基材（如纤维）具有极佳的拒水/拒油性。